R. Singh, K. Hristova, J. Fedacko, G. Elkilany, N. Verma
{"title":"Evolocumab和Alirocumab对急性冠状动脉综合征高危患者心血管结局的新临床试验","authors":"R. Singh, K. Hristova, J. Fedacko, G. Elkilany, N. Verma","doi":"10.17554/j.issn.2309-6861.2015.02.93","DOIUrl":null,"url":null,"abstract":"Evolocumab, alirocumab and bococizumab are leading monoclonal antibodies that are called Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. These agents have been used in multicenter studies to demonstrate their efficacy and safety and effect on blood lipoproteins as well as on cardiovascular outcomes indicating significant beneficial effects without much adverse effects.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"1 1","pages":"422-424"},"PeriodicalIF":0.0000,"publicationDate":"2015-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New Clinical Trials With Evolocumab and Alirocumab on Cardiovascular Outcomes, in Patients With High Rsk of Acute Coronary Syndromes\",\"authors\":\"R. Singh, K. Hristova, J. Fedacko, G. Elkilany, N. Verma\",\"doi\":\"10.17554/j.issn.2309-6861.2015.02.93\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Evolocumab, alirocumab and bococizumab are leading monoclonal antibodies that are called Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. These agents have been used in multicenter studies to demonstrate their efficacy and safety and effect on blood lipoproteins as well as on cardiovascular outcomes indicating significant beneficial effects without much adverse effects.\",\"PeriodicalId\":92802,\"journal\":{\"name\":\"Journal of clinical cardiology and cardiovascular therapy\",\"volume\":\"1 1\",\"pages\":\"422-424\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical cardiology and cardiovascular therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17554/j.issn.2309-6861.2015.02.93\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical cardiology and cardiovascular therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17554/j.issn.2309-6861.2015.02.93","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
Evolocumab、alirocumab和bococizumab是领先的单克隆抗体，被称为Proprotein convertase subtilisin/ keexin type 9 (PCSK9)抑制剂。这些药物已在多中心研究中使用，以证明其有效性和安全性，以及对血脂和心血管结局的影响，表明显着的有益效果而没有太多的不良反应。
New Clinical Trials With Evolocumab and Alirocumab on Cardiovascular Outcomes, in Patients With High Rsk of Acute Coronary Syndromes
Evolocumab, alirocumab and bococizumab are leading monoclonal antibodies that are called Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. These agents have been used in multicenter studies to demonstrate their efficacy and safety and effect on blood lipoproteins as well as on cardiovascular outcomes indicating significant beneficial effects without much adverse effects.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
